The reported incidence of cancers typically diagnosed in the outpatient setting may underestimate their true frequency, but the validity of mortality estimates from many of these causes has not been studied in detail. The authors sought to evaluate the validity of mortality estimation from death certificates for two such cancers, melanoma and mycosis fungoides (a cutaneous lymphoma), using routinely collected cancer registry data for 1973-1994 from the Surveillance, Epidemiology, and End Results program. Their method estimates that 93% of the deaths attributable to melanoma were certified as due to melanoma but that only 60% of the deaths attributable to mycosis fungoides were so certified. Evaluation of the accuracy of cause-of-death certification in this manner is helpful in the interpretation of mortality statistics. Am J Epidemiol 1998;148:1184-6. death certificates; melanoma; mortality; mycosis fungoides; registries Monitoring trends in cancers typically diagnosed on an outpatient basis has become a more difficult enterprise. Several studies have now demonstrated a degree of underregistration of melanoma in otherwise highquality, comprehensive, population-based cancer registries (1-4), such as the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (5), as well as state cancer registries unaffiliated with the national program (6, 7). Similar degrees of underregistration have been noted for mycosis fungoides, the most common form of cutaneous lymphoma (M. A. Weinstock and B. Gardstein, unpublished manuscript). This problem has been attributed to changes in the delivery of health care in the United States during recent years.
importance of the assessment of mortality in monitoring overall progress in the control of these disorders. This has been a particularly prominent feature of efforts aimed at understanding and controlling the burden of melanoma (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) and has also been used for evaluation of treatment and for etiologic inference in mycosis fungoides (19) (20) (21) . However, the validity of death certification for melanoma has received little attention, and even less attention has been paid to documenting the validity of certification of cutaneous lymphoma deaths. Deaths attributed to another cutaneous malignancy, squamous cell carcinoma, have been demonstrated to be substantially misclassified (22, 23) . In the case of melanoma, the cause-of-death information has generally been assumed to be accurate, and the meager published evidence supports that assumption (24) .
The purpose of this report is to evaluate the validity of the cause-of-death certification for these two diagnoses. We are unaware of previous use of this method for this purpose.
MATERIALS AND METHODS
The data used for these analyses derive from the system of population-based cancer registries maintained by the SEER program of the National Cancer Institute. These registries seek to include all malignancies (other than basal and squamous cell carcinomas of the skin) diagnosed among residents of their respective geographic areas, which are the metropolitan areas of Atlanta, Georgia; Detroit, Michigan; San Francisco, [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] , and our data include follow-up through 1994. We chose this group of cases to secure a minimum of 11 years of follow-up for the entire group.
Registered cases were followed for survival. For those cases who died during 1973-1978, the cause of death was coded according to the International Classification of Diseases, Eighth Revision (ICD-8); subsequent deaths were coded according to the Ninth Revision (ICD-9). Melanoma deaths were defined to include ICD-8 and ICD-9 codes 172.0-172.9 for the entire period. For mycosis fungoides, the ICD-8 code was 202.1, and the ICD-9 codes were 202.1 and 202.2.
Relative survival rates were calculated using the Survival program provided by the SEER program, which estimates expected survival on the basis of age, race, and gender by using the life tables provided by the United States Bureau of the Census. Individuals of unknown race, those of a racial group for which no life table was available, and those who were ascertained by death certificate or autopsy only were excluded from these analyses because the life tables for estimating the expected number of deaths did not apply to these groups.
Our assessment of validity of the cause-of-death information was based on the assumption that among groups of people with a malignancy followed until their relative survival curves are flat, i.e., until their survival experience is approximately equal to the expected survival experience of the general population, the difference between the number of deaths observed and the number of deaths expected based on general population rates should approximate the number of deaths attributed to the malignancy on the death certificate. We determined that for patients diagnosed during 1973-1983 the relative survival curves were essentially flat more than 11 years after diagnosis for both melanoma (Weinstock MA, unpublished data) and mycosis fungoides (25) . Hence, we chose an 11-year follow-up interval for study. For these groups, we used the Survival program to calculate the numbers of observed and expected deaths for each year of follow-up and subtracted the latter from the former to estimate the number of deaths attributable to the mahgnancy in these data. The number of deaths from this cause based on cause-of-death certification was then divided by this number to yield the "certification proportion," which, in theory, should approximate 100 percent.
The certification proportion could have been calculated even if the relative survival curves were not flat after the study interval. However, because the certification proportion may vary with time since diagnosis, we preferred to use the entire period of excess mortality to estimate a certification proportion that would be most useful in the interpretation of cause-specific mortality statistics.
RESULTS
For melanoma, 8,200 deaths were observed among cases diagnosed during 1973-1983. Of these, 48 were excluded due to unknown race, six due to "other" race (as defined by SEER detailed race coding), and 49 due to ascertainment by death certificate or autopsy, for a total of 103 excluded cases (1.3 percent of the deaths). The final analysis included the remaining 8,097 cases. The expected number of deaths for this group (based on life tables) was 3,860, so the remaining 4,237 were attributable to melanoma. According to the cause-ofdeath coding, 3,946 were actually attributed to melanoma, which represents 93 percent of the number attributable to this cause.
For mycosis fungoides, 430 deaths were observed among cases diagnosed during 1973-1983. Of these, three were excluded due to unknown race, two due to other race, and two due to ascertainment by death certificate or autopsy only. In total, seven (1.6 percent of deaths) were excluded; hence, 423 were available for analysis. The expected number of deaths in this group was 178, so 245 were attributable to mycosis fungoides. However, according to the cause-of-death coding, only 146 deaths were due to this cause, which represented 60 percent of the number attributable to this cause (the certification proportion). An additional 39 deaths (16 percent of the total) were classified as due to lymphoma of other or unspecified types; therefore, the total number of lymphoma deaths was 185, 76 percent of the number attributable to mycosis fungoides. Among these 39 deaths, the registry data had no record of another malignancy either prior to or subsequent to the mycosis fungoides for 28 cases (72 percent). Fifty-seven (24 percent) of the nonlymphoma deaths were listed as due to malignancy, of which lung cancer (21 deaths), colorectal cancer (six deaths), and leukemia (six deaths) were the only sites responsible for more than five deaths. Other major categories were circulatory disorders (including cardiovascular and cerebrovascular disease), which were responsible for 76 deaths, pneumonia (11 deaths), chronic obstructive pulmonary disease (nine deaths), and sepsis (five deaths). We examined the distribution of the certification proportion by category of age, gender, race, and year of diagnosis, but found no major differences among these categories.
DISCUSSION
We have described a method for assessment of the validity of cause-of-death certification for malignanAm J Epidemiol Vol. 148, No. 12, 1998 cies by using cancer registry data, but not involving rereview of medical records. We used this method to assess the validity of cause-of-death certification for two cancer sites commonly diagnosed on an outpatient basis, for which registry data may underestimate incidence. Our analyses suggest that melanoma deaths are accurately certified, but that a substantial proportion of mycosis fungoides deaths are misclassified as due to another cause.
The source of error in the certification of mycosis fungoides deaths is unclear, and several possibilities must be considered. Some of the error appears to be due to misclassification of the advanced stages of this disease as some other or unspecified form of lymphoma. The possibility that some nonlymphoma malignancies may have been induced by the mycosis fungoides or the therapy for it cannot be ruled out. However, we must also consider the likelihood that the disease or its therapy may have reduced the survivability of (or perhaps induced) other conditions that were ultimately responsible for death among patients with this generally relatively indolent disorder.
We must also consider a methodological component to some of the discrepancy noted. In particular, since our method is indirect, we could have been misled if the types of people who develop mycosis fungoides were otherwise likely to have a life expectancy greater than that of the general population. However, we believe this to be quite unlikely, given the magnitude of the observed differences for mycosis fungoides and the absence of a similar difference for melanoma, even though the latter is directly associated with socioeconomic status.
Our analyses pertain to the United States, and we would be reluctant to apply our conclusions to other countries. It would be worthwhile to determine the extent to which these findings can be generalized.
We now consider the confidence previously placed in the use of melanoma mortality statistics to be reinforced, but that mycosis fungoides mortality must be interpreted more cautiously, since a substantial minority of deaths may be missed by routine cause-of-death certification. More-detailed investigation into the cause of this inaccuracy would be worthwhile.
